Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Creative Medical Technology Holdings (CELZ) Equity Average (2016 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed Equity Average for 15 consecutive years, with $6.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 12.36% to $6.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.2 million, a 12.36% decrease, with the full-year FY2024 number at $8.3 million, down 36.34% from a year prior.
  • Equity Average was $6.2 million for Q3 2025 at Creative Medical Technology Holdings, down from $7.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $22.6 million in Q3 2022 to a low of -$21.1 million in Q1 2021.
  • A 5-year average of $8.2 million and a median of $8.4 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: tumbled 275.39% in 2021, then soared 4285.9% in 2022.
  • Creative Medical Technology Holdings' Equity Average stood at $4.9 million in 2021, then soared by 284.96% to $19.0 million in 2022, then tumbled by 40.86% to $11.2 million in 2023, then crashed by 42.51% to $6.4 million in 2024, then fell by 3.72% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for CELZ's Equity Average are $6.2 million (Q3 2025), $7.4 million (Q2 2025), and $7.2 million (Q1 2025).